Details for Patent: 9,956,227
Which drugs does patent 9,956,227 protect, and when does it expire?
Patent 9,956,227 protects CAPLYTA and is included in one NDA.
This patent has forty-five patent family members in sixteen countries.
Summary for Patent: 9,956,227
| Title: | Method for the treatment of residual symptoms of schizophrenia |
| Abstract: | The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia. |
| Inventor(s): | Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle |
| Assignee: | Intra Cellular Therapies Inc |
| Application Number: | US15/101,874 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,956,227 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; Dosage form; |
Drugs Protected by US Patent 9,956,227
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 9,956,227 | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | 9,956,227 | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-001 | Dec 20, 2019 | RX | Yes | Yes | 9,956,227 | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,956,227
| PCT Information | |||
| PCT Filed | December 03, 2014 | PCT Application Number: | PCT/US2014/068443 |
| PCT Publication Date: | June 11, 2015 | PCT Publication Number: | WO2015/085004 |
International Family Members for US Patent 9,956,227
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014360452 | ⤷ Start Trial | |||
| Australia | 2019200301 | ⤷ Start Trial | |||
| Australia | 2020202386 | ⤷ Start Trial | |||
| Australia | 2021290277 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
